- Home
- VGZ vs EPIX Comparison
VGZ vs EPIX Comparison
Compare VGZ & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGZ
- EPIX
- Stock Information
- Founded
- VGZ 1983
- EPIX 2009
- Country
- VGZ United States
- EPIX Canada
- Employees
- VGZ N/A
- EPIX N/A
- Industry
- VGZ
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- VGZ
- EPIX Health Care
- Exchange
- VGZ Nasdaq
- EPIX Nasdaq
- Market Cap
- VGZ 70.7M
- EPIX 77.2M
- IPO Year
- VGZ N/A
- EPIX N/A
- Fundamental
- Price
- VGZ $0.61
- EPIX $1.76
- Analyst Decision
- VGZ Strong Buy
- EPIX Hold
- Analyst Count
- VGZ 1
- EPIX 3
- Target Price
- VGZ $2.75
- EPIX $2.00
- AVG Volume (30 Days)
- VGZ 248.6K
- EPIX 425.3K
- Earning Date
- VGZ 03-13-2025
- EPIX 02-11-2025
- Dividend Yield
- VGZ N/A
- EPIX N/A
- EPS Growth
- VGZ N/A
- EPIX N/A
- EPS
- VGZ 0.09
- EPIX N/A
- Revenue
- VGZ N/A
- EPIX N/A
- Revenue This Year
- VGZ N/A
- EPIX N/A
- Revenue Next Year
- VGZ N/A
- EPIX N/A
- P/E Ratio
- VGZ $6.33
- EPIX N/A
- Revenue Growth
- VGZ N/A
- EPIX N/A
- 52 Week Low
- VGZ $0.32
- EPIX $1.40
- 52 Week High
- VGZ $0.83
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- VGZ 60.15
- EPIX 46.81
- Support Level
- VGZ $0.55
- EPIX $1.72
- Resistance Level
- VGZ $0.59
- EPIX $1.85
- Average True Range (ATR)
- VGZ 0.02
- EPIX 0.08
- MACD
- VGZ 0.01
- EPIX 0.02
- Stochastic Oscillator
- VGZ 80.56
- EPIX 36.96
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects, which may lead to gold production or value adding strategic transactions. These activities are currently focused principally in Australia.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.